BRPI1011236A2 - métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) - Google Patents
métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)Info
- Publication number
- BRPI1011236A2 BRPI1011236A2 BRPI1011236A BRPI1011236A BRPI1011236A2 BR PI1011236 A2 BRPI1011236 A2 BR PI1011236A2 BR PI1011236 A BRPI1011236 A BR PI1011236A BR PI1011236 A BRPI1011236 A BR PI1011236A BR PI1011236 A2 BRPI1011236 A2 BR PI1011236A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptides
- compositions
- mtm1
- methods
- myotubular myopathy
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000003728 Centronuclear myopathy Diseases 0.000 title abstract 3
- 208000032978 Structural Congenital Myopathies Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03064—Phosphatidylinositol-3-phosphatase (3.1.3.64)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26873209P | 2009-06-15 | 2009-06-15 | |
| PCT/US2010/038703 WO2010148010A1 (en) | 2009-06-15 | 2010-06-15 | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011236A2 true BRPI1011236A2 (pt) | 2019-07-09 |
Family
ID=43356726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011236A BRPI1011236A2 (pt) | 2009-06-15 | 2010-06-15 | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8834866B2 (enExample) |
| EP (1) | EP2443155B1 (enExample) |
| JP (1) | JP6166041B2 (enExample) |
| AU (1) | AU2010260145B2 (enExample) |
| BR (1) | BRPI1011236A2 (enExample) |
| CA (1) | CA2797480A1 (enExample) |
| ES (1) | ES2630057T3 (enExample) |
| WO (1) | WO2010148010A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1011236A2 (pt) | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
| ES2744840T3 (es) | 2011-04-01 | 2020-02-26 | Univ Yale | Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN |
| CA2907072A1 (en) * | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| US9732146B2 (en) * | 2012-03-30 | 2017-08-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Antibody-mediated transduction of heat shock proteins into living cells |
| US20150152170A1 (en) * | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| US8957044B2 (en) * | 2013-03-01 | 2015-02-17 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
| FR3004463A1 (fr) | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| JP6709733B2 (ja) * | 2014-01-13 | 2020-06-17 | バレリオン セラピューティクス， エルエルシー | 内在化部分 |
| EP3110844B1 (en) * | 2014-02-28 | 2020-02-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| WO2015192092A1 (en) * | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| AU2015308894A1 (en) | 2014-08-27 | 2017-03-23 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| US10383945B2 (en) | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
| CA3027960C (en) | 2016-06-15 | 2022-06-14 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| JP2019535645A (ja) | 2016-09-09 | 2019-12-12 | バレリオン セラピューティクス， エルエルシー | ラフォラ病の処置のための方法及び組成物 |
| CA3067497A1 (en) * | 2017-07-03 | 2019-01-10 | Universite De Strasbourg | Mtmr2-s polypeptide for use in the treatment of myopathies |
| KR20220101073A (ko) * | 2019-08-30 | 2022-07-19 | 예일 유니버시티 | 핵산을 세포로 전달하기 위한 조성물 및 방법 |
| JP2024508309A (ja) * | 2021-03-03 | 2024-02-26 | イエール ユニバーシティ | 骨格筋疾患を治療するための組成物及び方法 |
| GB202201713D0 (en) * | 2022-02-10 | 2022-03-30 | Univ Dundee | An affinity directed phosphatase system for targeted protein dephosphorylation |
| WO2024238807A2 (en) | 2023-05-16 | 2024-11-21 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
| US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| JP2000507225A (ja) | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム |
| US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
| JPH11151088A (ja) | 1997-11-20 | 1999-06-08 | Univ Tokyo | 脱リン酸化反応を触媒する新規酵素 |
| US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
| US6174687B1 (en) | 1999-02-26 | 2001-01-16 | The Burnham Institute | Methods of identifying lung homing molecules using membrane dipeptidase |
| US6303573B1 (en) | 1999-06-07 | 2001-10-16 | The Burnham Institute | Heart homing peptides and methods of using same |
| US6551809B2 (en) | 2001-03-20 | 2003-04-22 | Applera Corporation | Isolated human phosphatase proteins, nucleic acid molecules encoding human phophatase proteins, and uses thereof |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7316998B2 (en) * | 2004-05-27 | 2008-01-08 | Acceleron Pharma Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2010516708A (ja) * | 2007-01-22 | 2010-05-20 | アメリカ合衆国 | 抗体結合体の使用 |
| EP2164875A4 (en) | 2007-05-24 | 2011-11-30 | Us Dept Veterans Affairs | INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY |
| WO2010044894A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| CA2799608C (en) | 2009-05-28 | 2023-02-28 | Richard H. Weisbart | Amino acid sequences which enhance peptide conjugate solubility |
| BRPI1011236A2 (pt) | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
| GB2476671B (en) | 2010-01-04 | 2014-11-26 | Plastic Logic Ltd | Touch-sensing systems |
| JP5240316B2 (ja) | 2010-10-26 | 2013-07-17 | 株式会社デンソー | 車両乗員非操作運転システム |
| KR20140035357A (ko) | 2011-04-05 | 2014-03-21 | 셰브런 오로나이트 컴퍼니 엘엘씨 | 저점도 선박 실린더 윤활유 조성물 |
| US20150152170A1 (en) | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
-
2010
- 2010-06-15 BR BRPI1011236A patent/BRPI1011236A2/pt not_active Application Discontinuation
- 2010-06-15 AU AU2010260145A patent/AU2010260145B2/en not_active Ceased
- 2010-06-15 WO PCT/US2010/038703 patent/WO2010148010A1/en not_active Ceased
- 2010-06-15 CA CA2797480A patent/CA2797480A1/en not_active Abandoned
- 2010-06-15 ES ES10790070.6T patent/ES2630057T3/es active Active
- 2010-06-15 US US13/378,283 patent/US8834866B2/en not_active Expired - Fee Related
- 2010-06-15 JP JP2012515229A patent/JP6166041B2/ja not_active Expired - Fee Related
- 2010-06-15 EP EP10790070.6A patent/EP2443155B1/en not_active Not-in-force
-
2014
- 2014-09-12 US US14/485,524 patent/US9447394B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012529891A (ja) | 2012-11-29 |
| AU2010260145A1 (en) | 2012-02-02 |
| US20150218540A1 (en) | 2015-08-06 |
| ES2630057T3 (es) | 2017-08-17 |
| EP2443155A1 (en) | 2012-04-25 |
| CA2797480A1 (en) | 2010-12-23 |
| US20120213760A1 (en) | 2012-08-23 |
| US9447394B2 (en) | 2016-09-20 |
| EP2443155B1 (en) | 2017-03-29 |
| WO2010148010A1 (en) | 2010-12-23 |
| US8834866B2 (en) | 2014-09-16 |
| EP2443155A4 (en) | 2012-12-26 |
| JP6166041B2 (ja) | 2017-07-19 |
| AU2010260145B2 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011236A2 (pt) | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
| CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| MX347525B (es) | Inhibidores de tirosina cinasa de bruton. | |
| BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
| EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
| BRPI0922350A2 (pt) | anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. | |
| BR112013010574A2 (pt) | anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo | |
| CR9933A (es) | Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias | |
| BR112017001010A2 (pt) | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| IN2015DN00376A (enExample) | ||
| MX361778B (es) | Composiciones farmaceuticas y metodos de tratamiento. | |
| BR112013004685A2 (pt) | composição e método para reparação e regeneração muscular | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| CL2012002031A1 (es) | Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente. | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| BR112015027528A2 (pt) | polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |